GlaxoSmithKline Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹1,184 crore and net profit of ₹336 crore for the September 2026 quarter.
GlaxoSmithKline Pharmaceuticals (NSE: GLAXO) closed at ₹2,727.60 on 20 Nov 2026, up 8.7% over the past year. Its market capitalisation is ₹46,207 crore and it trades at 40.8 times earnings.
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.